Anti-CD40L antibody [MR1] (FITC) (ab24934)


  • Product nameAnti-CD40L antibody [MR1] (FITC)
    See all CD40L primary antibodies
  • Description
    Armenian Hamster monoclonal [MR1] to CD40L (FITC)
  • ConjugationFITC. Ex: 493nm, Em: 528nm
  • Specificityab24934 recognises CD40L.
  • Tested applicationsSuitable for: Blocking, Flow Cyt, IPmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    Tissue/ cell preparation: Activated mouse Th1 clone D1.6.

  • Positive control
    • Partially purified spleen T cells from BALB/c mice.



Our Abpromise guarantee covers the use of ab24934 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Blocking Use at an assay dependent concentration. In vivo and in vitro blocking of CD40L function.
Flow Cyt Use 2µg for 106 cells. ab18473-Armenian Hamster monoclonal IgG, is suitable for use as an isotype control with this antibody.
IP Use at an assay dependent concentration.


  • FunctionMediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching.
    Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway.
  • Tissue specificitySpecifically expressed on activated CD4+ T-lymphocytes.
  • Involvement in diseaseDefects in CD40LG are the cause of X-linked immunodeficiency with hyper-IgM type 1 (HIGM1) [MIM:308230]; also known as X-linked hyper IgM syndrome (XHIM). HIGM1 is an immunoglobulin isotype switch defect characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. Affected males present at an early age (usually within the first year of life) recurrent bacterial and opportunistic infections, including Pneumocystis carinii pneumonia and intractable diarrhea due to cryptosporidium infection. Despite substitution treatment with intravenous immunoglobulin, the overall prognosis is rather poor, with a death rate of about 10% before adolescence.
  • Sequence similaritiesBelongs to the tumor necrosis factor family.
  • Post-translational
    The soluble form derives from the membrane form by proteolytic processing.
    N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40.
    Not O-glycosylated.
  • Cellular localizationSecreted and Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD 40L antibody
    • CD154 antibody
    • CD40 antigen ligand antibody
    • CD40 ligand antibody
    • CD40 ligand, soluble form antibody
    • CD40-L antibody
    • CD40L antibody
    • CD40L_HUMAN antibody
    • CD40LG antibody
    • gp39 antibody
    • hCD40L antibody
    • HIGM1 antibody
    • IGM antibody
    • IMD3 antibody
    • T B cell activating molecule antibody
    • T BAM antibody
    • T-cell antigen Gp39 antibody
    • TNF-related activation protein antibody
    • TNFSF5 antibody
    • TrAP antibody
    • Tumor necrosis factor (ligand) superfamily member 5 antibody
    • Tumor necrosis factor ligand superfamily member 5 antibody
    see all

Anti-CD40L antibody [MR1] (FITC) images

  • Partially purified spleen T cells from BALB/c mice were incubated with either hamster IgG or plate bound hamster anti mouse CD3 epsilon for 7 hours at 37°C. The cells were then harvested, double stained with ab24934 (2µg for 106 cells) and anti CD4+8 PE, and analyzed by flow cytometry.

References for Anti-CD40L antibody [MR1] (FITC) (ab24934)

ab24934 has not yet been referenced specifically in any publications.

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Flow Cytometry
Sample Mouse Cell (lymphocytes and granulocytes)
Specification lymphocytes and granulocytes
Permeabilization No

Mrs. Ann Kelly

Verified customer

Submitted Dec 05 2006